Ascelia_Pharma

Chimeric Therapeutics

ASX: CHM

Market CapAU$26m

Last Close AU$0.08

Australian-based Chimeric Therapeutics recently went public on the ASX. CLTX CAR T is in Phase I for the treatment of GBM. The technology may have applicability for other tumours such as melanoma. Chimeric recently in-licensed a CDH17 CAR T for use in solid tumours and the CORE-NK platform, which may have broad applicability in cancer.

More Chimeric Therapeutics content >

Investment summary

Chimeric has announced that it has entered into an exclusive option agreement to license the clinically validated, off the shelf, robust, enhanced natural killer (CORE-NK) cell platform from Case Western Reserve University for the treatment of cancer. The CORE-NK platform was designed to overcome the hurdles associated with NK cell development and enables the production of large numbers of highly active universal donor NK cells that are active in the body. The company expects to rapidly move to complete full licensing of the platform.

Y/E Jun
Revenue (A$m)
EBITDA (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2020A 0.0 (0.1) (0.1) (6200.80) N/A N/A
2021A 0.0 (14.8) (14.9) (8.16) N/A N/A
2022E 0.0 (14.0) (14.0) (4.19) N/A N/A
2023E 0.0 (14.5) (14.5) (4.32) N/A N/A
Content on Chimeric Therapeutics
Chimeric Therapeutics – Acquiring an exciting new NK cell technology
Healthcare | research Update | 6 December 2021
Healthcare Sector reports: T-cell therapies Part 1-17092017-Feature image
Chimeric Therapeutics – Scorpion venom CAR-T stalking GBM
Healthcare | research Initiation | 19 January 2021
Healthcare Sector reports: T-cell therapies Part 1-17092017-Feature image
View more
Register to receive research on Chimeric Therapeutics as it is published
Share price graph
Balance sheet
Forecast net cash (A$m) 8.1
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (2.4) (27.8) (68.1)
Relative* (7.9) (30.3) (67.7)
52-week high/low A$0.3/A$0.1
*% relative to local index
Key management
Jennifer Chow CEO
Paul Hopper Executive Chairman